Geniposide

Geniposide at a Glance

Geniposide is an iridoid glucoside — the principal iridoid of gardenia fruit (Gardenia jasminoides; zhi zi / Gardeniae Fructus in Chinese medicine) and the glucoside precursor of genipin, the reactive aglycone behind the traditional “gardenia blue” dye. It sits in the same iridoid-glycoside family as aucubin and harpagide, stored inert as the sugar-bound molecule and activated when a glucosidase cleaves the sugar.

Its preclinical literature is unusually large and coherent, and it has an elegant organising principle: geniposide is one of the few non-peptide agonists of the glucagon-like peptide-1 receptor (GLP-1R) ^{3,4Reference 3Liu J et al. · 2007Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathwayView study →Reference 4Gong N et al. · 2014Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptorsView study →}. That single mechanism threads through most of its reported activities — hepatoprotective and anti-steatotic, anti-diabetic, neuroprotective, cardioprotective and analgesic — but essentially all of it is rodent or cell work on the isolate, and gardenia’s human record belongs to the whole herb and its formulas, not to purified geniposide.

The load-bearing honesty here is two-sided. The same molecule that protects the liver in one set of models injures it in another — a real, dose- and time-dependent hepatotoxicity mediated by the gut-released aglycone genipin ^{10,11,12Reference 10Yamano T et al. · 1990AnimalHepatotoxicity of geniposide in ratsView study →Reference 11Tian J et al. · 2017Dose-related liver injury of Geniposide associated with the alteration in bile acid synthesis and transportationView study →Reference 12Qiu J et al. · 2024Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatmentView study →}. That is why the page carries a moderate flag and gives the toxicity its own section.

Geniposide & Genipin

The single most important fact about this molecule is that geniposide and genipin are two different actors, and most of the interesting biology — good and bad — is a story about the glucoside becoming the aglycone.

Geniposide is the intact glucoside (genipin 1-O-β-D-glucoside). It is water-soluble, poorly absorbed across the gut wall, and it is the form shown to act at the GLP-1 receptor in the receptor/behaviour studies ^{3,4Reference 3Liu J et al. · 2007Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathwayView study →Reference 4Gong N et al. · 2014Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptorsView study →}.

Genipin is the aglycone, liberated when gut-microbial β-glucosidase removes the sugar ^{9Reference 9Jin MJ et al. · 2014AnimalEffects of intestinal microbiota on the bioavailability of geniposide in ratsView study →}. Genipin is a small, chemically reactive iridoid: in the presence of oxygen and primary amines it spontaneously crosslinks proteins into a blue pigment — the basis of gardenia-blue food colour and of genipin’s use as a low-toxicity biological crosslinker (roughly ten-thousand-fold less cytotoxic than glutaraldehyde) in tissue engineering and drug-delivery scaffolds ^{15Reference 15Sobolewska D et al. · 2025ReviewGenipin — Simple but Significant Bioactive Iridoid for Therapeutical Application and Beyond: A ReviewView study →}. Genipin is also a mitochondrial UCP2 inhibitor, the mechanism behind much of its own antioxidant and anticancer pharmacology ^{15Reference 15Sobolewska D et al. · 2025ReviewGenipin — Simple but Significant Bioactive Iridoid for Therapeutical Application and Beyond: A ReviewView study →}.

That same reactivity is the toxic mechanism. Genipin can form dialdehyde/iminium intermediates that covalently bind hepatic proteins and deplete protective sulfhydryls, which is why the earliest rat work tied geniposide’s liver injury to its conversion to genipin and found liver thiols protective ^{10Reference 10Yamano T et al. · 1990AnimalHepatotoxicity of geniposide in ratsView study →}. So the glucoside → aglycone step is the hinge: it is how an orally poorly-absorbed sugar conjugate becomes a reactive, crosslinking, both-bioactive-and-hepatotoxic small molecule. Read every claim below with that split in mind — where the evidence is for geniposide (GLP-1R signalling) versus for genipin (UCP2, crosslinking, covalent binding).

Therapeutic Promise vs. Hepatotoxicity

Geniposide is the rare herbal molecule whose promise and hazard point at the same organ. The preclinical case for it is genuinely attractive: as a GLP-1R agonist it improves hepatic steatosis, glucose and lipid handling in NAFLD and diabetes models ^{3,5,6Reference 3Liu J et al. · 2007Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathwayView study →Reference 5Ma ZG et al. · 2016Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor / AMPKα signalling pathwayView study →Reference 6Shen B et al. · 2020Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signalling pathwaysView study →}, with the kind of metabolic profile that has made the peptide GLP-1 drugs transformative. Yet the same compound produces dose-dependent liver injury above a threshold — the opposite of hepatoprotection ^{11,12Reference 11Tian J et al. · 2017Dose-related liver injury of Geniposide associated with the alteration in bile acid synthesis and transportationView study →Reference 12Qiu J et al. · 2024Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatmentView study →}.

The reconciliation is dose and time, not contradiction:

• At lower doses / shorter courses, geniposide improves bile-acid and lipid metabolism and protects the liver in disease models ^{6,12Reference 6Shen B et al. · 2020Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signalling pathwaysView study →Reference 12Qiu J et al. · 2024Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatmentView study →}.
• At higher doses or prolonged dosing, it down-regulates the bile-acid regulators FXR/SHP/BSEP, causes cholestatic bile-acid accumulation, activates the NLRP3 inflammasome, and raises transaminases and histological injury ^{11,14Reference 11Tian J et al. · 2017Dose-related liver injury of Geniposide associated with the alteration in bile acid synthesis and transportationView study →Reference 14Liu Y et al. · 2025NLRP3 Inflammasome Activation Is Involved in Geniposide-Induced HepatotoxicityView study →}; a dedicated 2024 study frames the whole thing explicitly as a therapeutic-window problem where higher doses and longer durations become harmful, especially in an already-diseased (NAFLD) liver ^{12Reference 12Qiu J et al. · 2024Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatmentView study →}.

This is why the toxicity badge is moderate rather than low: the injury is real, reproducible, mechanistically explained (genipin-mediated covalent binding + bile-acid dysregulation + NLRP3), and it lands on the very organ the molecule is proposed to help. It is also why “gardenia is a traditional medicine, therefore safe” does not follow — the traditional dose is a whole-herb decoction, not a concentrated isolate given long-term.

What It's Used For

Geniposide’s profile is broad, internally consistent and organised around the GLP-1 receptor — but the compound-page discipline is decisive here: no human trials of the isolate, all efficacy data are rodent/cell, and the parallel hepatotoxicity signal caps how far any of it can be pushed.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. No human isolate data exist, so scores stay modest by design; they rank the preclinical weight, not clinical proof.

01Hepatoprotective / anti-steatotic (NAFLD)Shaky44%Rodent NAFLD Nrf2/AMPK/mTOR + reviews — but dose-capped by hepatotoxicity ^{1,2,6Reference 1Shan M et al. · 2017ReviewA Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural ProductView study →Reference 2Liu L et al. · 2022Updated Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of Natural Product GeniposideView study →Reference 6Shen B et al. · 2020Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signalling pathwaysView study →}

02Anti-diabetic / metabolic (GLP-1R)Shaky40%GLP-1R agonism, glucose–lipid & insulin-secretion models ^{1,3Reference 1Shan M et al. · 2017ReviewA Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural ProductView study →Reference 3Liu J et al. · 2007Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathwayView study →}

03NeuroprotectiveShaky38%Alzheimer, depression and PC12 models via GLP-1R/mTOR/autophagy ^{3,7,8Reference 3Liu J et al. · 2007Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathwayView study →Reference 7Zhang Z et al. · 2019AnimalGeniposide-mediated protection against amyloid deposition and behavioral impairment correlates with downregulation of mTOR signaling and enhanced autophagy in a mouse model of Alzheimer’s diseaseView study →Reference 8Zhao Y et al. · 2018AnimalGeniposide improves repeated restraint stress-induced depression-like behavior in mice by ameliorating neuronal apoptosis via regulating GLP-1R/AKT signaling pathwayView study →}

04CardioprotectiveShaky30%Anti-hypertrophy via GLP-1R/AMPKα in mice ^{5Reference 5Ma ZG et al. · 2016Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor / AMPKα signalling pathwayView study →}

05Analgesic / antinociceptiveShaky28%Intrathecal geniposide + iridoid analogs at spinal GLP-1Rs ^{4Reference 4Gong N et al. · 2014Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptorsView study →}

06Anti-inflammatoryShaky26%Cross-cutting NF-κB / NLRP3 / TLR4 suppression ^{1,2Reference 1Shan M et al. · 2017ReviewA Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural ProductView study →Reference 2Liu L et al. · 2022Updated Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of Natural Product GeniposideView study →}

Mechanisms

The load-bearing pattern is a single receptor (GLP-1R) fanning out into hepatic, metabolic, neural and cardiac protection for the glucoside — while a separate reactive chemistry of the aglycone genipin (UCP2, crosslinking, covalent binding) supplies both its dye/biomaterial uses and its toxicity.

Pharmacokinetics

Geniposide behaves like a typical poorly-absorbed iridoid glucoside: oral bioavailability of the pure compound is low — single-digit percent in rats — and is substantially higher when dosed as the whole gardenia extract rather than the isolate, implicating the plant matrix and gut flora in its handling ^{1Reference 1Shan M et al. · 2017ReviewA Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural ProductView study →}. Its metabolism is gut-microbiota-dependent: intestinal β-glucosidase hydrolyses geniposide to genipin, which is then conjugated (genipin sulfate/glucuronide); when antibiotics deplete the microbiota, geniposide’s own systemic exposure rises while genipin exposure falls, confirming that the flora, not the host gut wall, controls the glucoside→aglycone switch ^{9Reference 9Jin MJ et al. · 2014AnimalEffects of intestinal microbiota on the bioavailability of geniposide in ratsView study →}. Two consequences define the molecule: (1) in-vitro potency of geniposide overreads what an oral dose delivers of the intact glucoside; and (2) the pharmacology and the toxicology both partly belong to genipin, whose formation depends on an individual’s gut microbiome — a source of variability in both effect and risk ^{1,9Reference 1Shan M et al. · 2017ReviewA Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural ProductView study →Reference 9Jin MJ et al. · 2014AnimalEffects of intestinal microbiota on the bioavailability of geniposide in ratsView study →}.

Clinical Trials

There are no controlled human trials of isolated geniposide. Gardenia fruit (zhi zi) has a long traditional-medicine record within multi-herb formulas, but that is whole-herb use, not evidence for the purified molecule, and the human safety questions raised by the animal hepatotoxicity data have not been resolved in the isolate.

Last checked: July 2026.

Isolate vs. Plant Studies

The split is clean and cuts in the usual direction. The entire mechanistic and efficacy literature — GLP-1R agonism, NAFLD/AMPK/Nrf2, Alzheimer mTOR/autophagy, cardiac anti-hypertrophy, spinal antinociception — is done with isolated geniposide (or genipin) in rodents and cell lines ^{3,4,5,6,7,8Reference 3Liu J et al. · 2007Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathwayView study →Reference 4Gong N et al. · 2014Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptorsView study →Reference 5Ma ZG et al. · 2016Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor / AMPKα signalling pathwayView study →Reference 6Shen B et al. · 2020Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signalling pathwaysView study →Reference 7Zhang Z et al. · 2019AnimalGeniposide-mediated protection against amyloid deposition and behavioral impairment correlates with downregulation of mTOR signaling and enhanced autophagy in a mouse model of Alzheimer’s diseaseView study →Reference 8Zhao Y et al. · 2018AnimalGeniposide improves repeated restraint stress-induced depression-like behavior in mice by ameliorating neuronal apoptosis via regulating GLP-1R/AKT signaling pathwayView study →}, which is a genuine strength: those are the molecule’s own effects, not an extract’s. The weakness is that there are no human isolate trials at all, so the clinical column is empty. The human side belongs to whole gardenia / zhi zi and traditional formulas, whose effects cannot be reduced to geniposide (gardenia fruit also carries geniposidic acid, genipin-1-gentiobioside, crocins and other actives). The toxicology sharpens the caveat: because a chunk of both activity and injury runs through the gut-generated aglycone genipin ^{9,10Reference 9Jin MJ et al. · 2014AnimalEffects of intestinal microbiota on the bioavailability of geniposide in ratsView study →Reference 10Yamano T et al. · 1990AnimalHepatotoxicity of geniposide in ratsView study →}, whole-herb behaviour and isolate behaviour can diverge, and neither maps cleanly onto a human oral dose.

Its Role in Plants

In gardenia, geniposide is a defensive iridoid glucoside, stored inert as the water-soluble sugar conjugate. Iridoid glycosides are bitter deterrents whose ecological function is chemical defence: kept separate from activating enzymes in intact tissue, they are cleaved by β-glucosidase on wounding or ingestion to release the reactive aglycone — here genipin, which crosslinks proteins and can deter or harm herbivores and microbes ^{15Reference 15Sobolewska D et al. · 2025ReviewGenipin — Simple but Significant Bioactive Iridoid for Therapeutical Application and Beyond: A ReviewView study →}. This enzyme-triggered activation is the same chemistry that governs the molecule’s pharmacokinetics and its dye behaviour, and it is shared across the iridoid siblings aucubin and harpagide and their reactive aglycones.

As always, a constituent’s defensive role in the plant is plant biology, not human pharmacology, and does not predict what it does as a medicine.

Prevalence in Nature

Geniposide is best known as the principal iridoid glucoside of gardenia fruit (Gardenia jasminoides, Rubiaceae) — the dried ripe fruit zhi zi / Gardeniae Fructus of Chinese medicine — where it is a major constituent, commonly a few percent of the dried fruit and the marker compound used to standardise the crude drug ^{1,2Reference 1Shan M et al. · 2017ReviewA Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural ProductView study →Reference 2Liu L et al. · 2022Updated Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of Natural Product GeniposideView study →}. It co-occurs there with related iridoids (geniposidic acid, genipin-1-gentiobioside) and with the crocin pigments that colour the fruit. Beyond gardenia it is reported from Eucommia ulmoides (du zhong) and scattered other Gentianales, but gardenia is overwhelmingly the source that matters — botanically and for every study cited here. Absolute content varies with cultivar, ripeness, plant part and processing, and the processed (roasted/charred) forms of zhi zi carry different iridoid profiles from the raw fruit ^{1Reference 1Shan M et al. · 2017ReviewA Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural ProductView study →}.

Discovery & Synthesis

Geniposide was isolated from the fruit of Gardenia jasminoides in the mid-twentieth-century effort to characterise the bitter iridoids of the gardenia fruit, and its name traces to its aglycone genipin — itself named from genipa/Genipa americana, the New-World relative whose fruit yields the same blue-forming iridoid used as a body/dye pigment. The molecule’s cultural footprint long predates its pharmacology: gardenia blue, produced when genipin reacts with amino acids and proteins, has been used as a colourant in East Asia for centuries, and the fruit (zhi zi) as a traditional remedy for inflammation and jaundice ^{15Reference 15Sobolewska D et al. · 2025ReviewGenipin — Simple but Significant Bioactive Iridoid for Therapeutical Application and Beyond: A ReviewView study →}. Manufacture today is by extraction from gardenia fruit, an abundant and cheap source; geniposide is also the industrial feedstock from which genipin is obtained (by enzymatic or microbial hydrolysis) for use as a natural blue colourant and as a biocompatible protein crosslinker ^{15Reference 15Sobolewska D et al. · 2025ReviewGenipin — Simple but Significant Bioactive Iridoid for Therapeutical Application and Beyond: A ReviewView study →}. Total synthesis of the iridoid skeleton exists in the literature but is not the supply route — isolation from gardenia dominates.

Patents: not yet researched.

Toxicity & Safety

Geniposide carries a moderate flag — higher than a typical plant iridoid glucoside — because of a real, reproducible, dose- and time-dependent hepatotoxicity that is mechanistically understood and lands on the same organ the molecule is proposed to protect. This is not a theoretical concern extrapolated from chemistry; it is observed liver injury in multiple animal studies.

Safety at a Glance

⚠️ Moderate toxicity

• Whole gardenia fruit (zhi zi) has a long traditional record at culinary/decoction exposures, and low-dose geniposide is hepatoprotective in disease models ^{1,6Reference 1Shan M et al. · 2017ReviewA Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural ProductView study →Reference 6Shen B et al. · 2020Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signalling pathwaysView study →}.
• Dose-dependent liver injury above a threshold. Isolated geniposide raised transaminases and caused histological liver damage at higher doses (e.g. 300 mg/kg in rats), with cholestatic bile-acid dysregulation and NLRP3 activation ^{11,12,14Reference 11Tian J et al. · 2017Dose-related liver injury of Geniposide associated with the alteration in bile acid synthesis and transportationView study →Reference 12Qiu J et al. · 2024Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatmentView study →Reference 14Liu Y et al. · 2025NLRP3 Inflammasome Activation Is Involved in Geniposide-Induced HepatotoxicityView study →}.
• The aglycone genipin is the reactive culprit. Gut-released genipin covalently binds hepatic proteins and depletes protective sulfhydryls; genipin’s own LD50 is ~510 mg/kg in mice, with dose- and time-dependent (reversible) hepatotoxicity ^{10,13Reference 10Yamano T et al. · 1990AnimalHepatotoxicity of geniposide in ratsView study →Reference 13Wang S et al. · 2023AnimalAcute and subacute hepatotoxicity of genipin in mice and its potential mechanismView study →}.
• Higher and longer is worse, especially in a diseased liver. A dedicated study frames geniposide as a therapeutic-window problem where dose and duration flip it from protective to harmful in NAFLD models ^{12Reference 12Qiu J et al. · 2024Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatmentView study →}.
• No isolate human safety data, and gut-microbiome-dependent risk. Because injury runs through microbial genipin formation, exposure and risk vary between individuals; no comprehensive isolate toxicology or reproductive-safety package exists ^{9,12Reference 9Jin MJ et al. · 2014AnimalEffects of intestinal microbiota on the bioavailability of geniposide in ratsView study →Reference 12Qiu J et al. · 2024Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatmentView study →}.

Full Safety & Interactions Detail

The core signal — dose-dependent hepatotoxicity. The earliest rat work showed geniposide raises serum ALT/AST and that its conversion to genipin is central to the injury, with liver sulfhydryl compounds protective ^{10Reference 10Yamano T et al. · 1990AnimalHepatotoxicity of geniposide in ratsView study →}. A controlled dose study found 300 mg/kg (but not 100 mg/kg) geniposide for three days produced clear liver injury (ALT, AST, ALP, γ-GT up; histological change), with down-regulation of the bile-acid regulators FXR, SHP and BSEP and cholestatic accumulation of taurine-conjugated bile acids — a bile-acid-dysregulation mechanism ^{11Reference 11Tian J et al. · 2017Dose-related liver injury of Geniposide associated with the alteration in bile acid synthesis and transportationView study →}. The reactive aglycone genipin reproduces this on its own: dose- and time-dependent hepatotoxicity in mice, LD50 ~510 mg/kg, with disruption of hepatic drug-metabolising enzymes; encouragingly, the injury was reversible on withdrawal ^{13Reference 13Wang S et al. · 2023AnimalAcute and subacute hepatotoxicity of genipin in mice and its potential mechanismView study →}. A 2025 study implicates NLRP3 inflammasome activation (IL-1β/IL-18) in geniposide-induced liver injury, blunted by an NLRP3 inhibitor ^{14Reference 14Liu Y et al. · 2025NLRP3 Inflammasome Activation Is Involved in Geniposide-Induced HepatotoxicityView study →}.

The window, not a wall. A 2024 investigation reframes the whole picture as dose and time: geniposide benefits bile-acid and lipid metabolism at lower doses but harms intestinal and liver function at higher doses and longer durations, and the diseased (NAFLD) liver is more vulnerable ^{12Reference 12Qiu J et al. · 2024Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatmentView study →}. Subchronic dosing well below the toxic range (tens of mg/kg for 90 days in rats) did not produce hepatotoxicity in normal animals, consistent with a threshold effect ^{1Reference 1Shan M et al. · 2017ReviewA Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural ProductView study →}.

Interactions & scope. Because geniposide is bioactivated by gut-microbial β-glucosidase to genipin, factors that change the microbiome (antibiotics, disease) alter both exposure and metabolite formation ^{9Reference 9Jin MJ et al. · 2014AnimalEffects of intestinal microbiota on the bioavailability of geniposide in ratsView study →} — a plausible but unquantified source of variable response and risk in people. No dedicated human drug-interaction data exist for the isolate. Reproductive note (prose only): no dedicated reproductive-/developmental-toxicity dataset exists for isolated geniposide; pregnancy and lactation decisions belong to the gardenia (zhi zi) herb or product page where intake is decided, not to this molecule page. No comprehensive isolate genotoxicity or repeat-dose package beyond the hepatotoxicity work above is characterised here.

Dosage

There is no established or recommended human dose for isolated geniposide — it has never been given to people as a purified drug. Cited figures are preclinical rodent research doses, and this is a molecule where the dose direction is itself a safety point: the same compound is hepatoprotective at low doses and hepatotoxic at high ones, with liver injury reported around 300 mg/kg in rats and the aglycone genipin’s LD50 near 510 mg/kg in mice ^{11,12,13Reference 11Tian J et al. · 2017Dose-related liver injury of Geniposide associated with the alteration in bile acid synthesis and transportationView study →Reference 12Qiu J et al. · 2024Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatmentView study →Reference 13Wang S et al. · 2023AnimalAcute and subacute hepatotoxicity of genipin in mice and its potential mechanismView study →}. Human exposure occurs through whole gardenia fruit (zhi zi) and traditional multi-herb formulas — a decoction exposure, standardised (where it is) to geniposide as a marker, not a concentrated isolate taken long-term ^{1Reference 1Shan M et al. · 2017ReviewA Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural ProductView study →}. These are doses studied in research and are not a personal recommendation.

References

1. Shan M, et al. (2017). A Review on the Phytochemistry, Pharmacology, Pharmacokinetics and Toxicology of Geniposide, a Natural Product. Molecules. https://pubmed.ncbi.nlm.nih.gov/28994736/
2. Liu L, et al. (2022). Updated Pharmacological Effects, Molecular Mechanisms, and Therapeutic Potential of Natural Product Geniposide. Molecules. https://pubmed.ncbi.nlm.nih.gov/35630796/
3. Liu J, et al. (2007). Geniposide, a novel agonist for GLP-1 receptor, prevents PC12 cells from oxidative damage via MAP kinase pathway. Neurochemistry International. https://pubmed.ncbi.nlm.nih.gov/17629357/
4. Gong N, et al. (2014). Geniposide and its iridoid analogs exhibit antinociception by acting at the spinal GLP-1 receptors. Neuropharmacology. https://pubmed.ncbi.nlm.nih.gov/24747181/
5. Ma ZG, et al. (2016). Protection against cardiac hypertrophy by geniposide involves the GLP-1 receptor / AMPKα signalling pathway. British Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/26845648/
6. Shen B, et al. (2020). Geniposide alleviates non-alcohol fatty liver disease via regulating Nrf2/AMPK/mTOR signalling pathways. Journal of Cellular and Molecular Medicine. https://pubmed.ncbi.nlm.nih.gov/32293113/
7. Zhang Z, et al. (2019). Geniposide-mediated protection against amyloid deposition and behavioral impairment correlates with downregulation of mTOR signaling and enhanced autophagy in a mouse model of Alzheimer’s disease. Aging (Albany NY). https://pubmed.ncbi.nlm.nih.gov/30684442/
8. Zhao Y, et al. (2018). Geniposide improves repeated restraint stress-induced depression-like behavior in mice by ameliorating neuronal apoptosis via regulating GLP-1R/AKT signaling pathway. Neuroscience Letters. https://pubmed.ncbi.nlm.nih.gov/29626654/
9. Jin MJ, et al. (2014). Effects of intestinal microbiota on the bioavailability of geniposide in rats. Journal of Agricultural and Food Chemistry. https://pubmed.ncbi.nlm.nih.gov/25257195/
10. Yamano T, et al. (1990). Hepatotoxicity of geniposide in rats. Food and Chemical Toxicology. https://pubmed.ncbi.nlm.nih.gov/2210524/
11. Tian J, et al. (2017). Dose-related liver injury of Geniposide associated with the alteration in bile acid synthesis and transportation. Scientific Reports. https://pubmed.ncbi.nlm.nih.gov/28827769/
12. Qiu J, et al. (2024). Geniposide dosage and administration time: Balancing therapeutic benefits and adverse reactions in liver disease treatment. Phytomedicine. https://pubmed.ncbi.nlm.nih.gov/38968789/
13. Wang S, et al. (2023). Acute and subacute hepatotoxicity of genipin in mice and its potential mechanism. Heliyon. https://pubmed.ncbi.nlm.nih.gov/38027867/
14. Liu Y, et al. (2025). NLRP3 Inflammasome Activation Is Involved in Geniposide-Induced Hepatotoxicity. Mediators of Inflammation. https://pubmed.ncbi.nlm.nih.gov/39949920/
15. Sobolewska D, et al. (2025). Genipin — Simple but Significant Bioactive Iridoid for Therapeutical Application and Beyond: A Review. Life (Basel). https://pubmed.ncbi.nlm.nih.gov/40003568/

View all 15 references▾